metronomic chemo / TSP-1 Cancer Research Results

metroC, metronomic chemo: Click to Expand ⟱
Features:
Metronomic chemotherapy refers to the therapeutic strategy of administering chemotherapeutic drugs at relatively low, minimally toxic doses on a frequent or continuous schedule without extended rest periods. This dosing regimen contrasts with traditional maximum tolerated dose (MTD) chemotherapy, which involves high doses given intermittently with breaks to allow patient recovery.

-The drugs are given in lower doses and more frequently (often daily or multiple times a week)
-Aims to consistently impair tumor growth mechanisms and potentially minimize the chance for cancer cells to recover
-Aims to consistently impair tumor growth mechanisms and potentially minimize the chance for cancer cells to recover
-With a lower dose intensity, patients often experience fewer and less severe side effects
TSP-1, Thrombospondin-1: Click to Expand ⟱
Source:
Type:
(TSP-1) is the first reported endogenous anti-angiogenic factor that can inhibit angiogenesis and tumorigenesis.
Thrombospondin-1 (TSP-1) is a glycoprotein that plays a significant role in various biological processes, including cell adhesion, migration, and angiogenesis. It is part of the thrombospondin family of proteins and is known for its ability to regulate the formation of new blood vessels (angiogenesis) and modulate the immune response.
TSP-1 is often considered a tumor suppressor because it can inhibit angiogenesis by binding to and activating certain receptors on endothelial cells, leading to reduced blood vessel formation. This can limit the supply of nutrients and oxygen to tumors, potentially inhibiting their growth.
Scientific Papers found: Click to Expand⟱
2487- metroC,    Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma
- Review, HCC, NA
toxicity↓, toxicity↓, eff↝, angioG↓, CSCs↓, TSP-1↑, Hif1a↓, VEGF↓, eff↑,
2488- metroC,    Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma
- in-vitro, HCC, HUH7 - in-vivo, HCC, NA
TumCG↓, toxicity↓, OS↑, TSP-1↑, Dose↓, Dose↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   TumCG↓, 1,  

Migration ⓘ

TSP-1↑, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↓, 2,   eff↑, 1,   eff↝, 1,  

Functional Outcomes ⓘ

OS↑, 1,   toxicity↓, 3,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TSP-1, Thrombospondin-1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:327  Target#:320  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page